但这种垄断格局，即将被打破，多款在研新药正从作用机制到给药方式，向Vosoritide发起挑战。Ascendis的TransCon-CNP通过包裹技术延长了药物作用时间，实现了周剂给药，目前正处于FDA审批阶段；而BridgeBio的口服药Infigratinib，则从作用机制到用药体验实现全面突破。
The ISS is far bigger than either the Salyuts or Skylab. In an uncontrolled deorbit, pieces of debris “up to car and train size,” say experts on the official ISS space station advisory committee, will rain down from the sky. NASA confirms this would pose “a significant risk to the public worldwide.”
，更多细节参见safew官方版本下载
show how a website's pages rank for specific keywords
——“努力创造无愧于时代的新业绩”